X4 Pharmaceuticals, Inc. — Q1 2024 Form 10-Q
Business context and period: The filing covers the three months ended March 31, 2024. X4 is a biopharmaceutical company focused on rare immune-related diseases. After quarter-end, on April 29, 2024, the FDA approved mavorixafor as XOLREMDI for patients aged 12 and older with WHIM syndrome; the company reported that its U.S. launch was underway. The quarter’s financial statements therefore do not reflect product sales from the approved drug.
Key financial metrics
Amounts are in millions of dollars, except per-share data. X4 reported no product revenue for the quarter.
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Research and development expense | $19.9 | $22.1 |
| Selling, general and administrative expense | $17.4 | $7.2 |
| Total operating expenses | $37.3 | $29.3 |
| Net loss | $51.8 | $24.0 |
| Net loss per share, basic and diluted | $0.26 | $0.16 |
| Net cash used in operating activities | $33.6 | $26.5 |
| Cash, cash equivalents and short-term marketable securities at period-end | $80.9 | Not provided here |
| Long-term debt, net of discount | $54.8 | Not provided here |
At March 31, 2024, current assets were $87.3 million and current liabilities were $23.5 million. Cash and cash equivalents were $60.5 million; marketable securities were $20.4 million; restricted cash was $0.8 million. Stockholders’ equity was $1.0 million. The filing does not report product-sales margins; XOLREMDI royalties to Genzyme are tiered at 6% to 12% of annual net sales.
Changes versus the prior comparable period
- Operating expenses rose $8.0 million, chiefly from a $10.2 million increase in SG&A as X4 built its commercial organization and incurred pre-launch costs. R&D fell $2.2 million, partly because Q1 2023 included a $5.0 million Genzyme milestone and higher WHIM Phase 3 trial costs.
- Net loss increased $27.7 million. Other expense shifted from $5.3 million of income to $14.5 million of expense, primarily because the Class C warrant liability generated a $13.8 million noncash fair-value loss in Q1 2024, versus a $5.4 million gain in Q1 2023.
- Operating cash use increased $7.1 million, which management attributed largely to annual bonus payments and XOLREMDI pre-commercialization spending. Investing activities used $5.3 million, mainly for net purchases of short-term securities; financing cash flows were nil.
- Weighted-average shares used for EPS were 200.0 million versus 146.0 million. The filing’s EPS denominator includes pre-funded warrants with nominal remaining exercise prices; potential options, RSUs and other warrants were excluded as anti-dilutive.
Outlook, risks and notable items
- Going concern and funding: Management concluded substantial doubt exists about X4’s ability to continue as a going concern for at least one year after issuance of the financial statements. X4 said available cash, equivalents and marketable securities could fund operations into 2025, but projections show a likely breach of the Hercules loan’s minimum-cash covenant in Q1 2025 absent additional funding. The lender could demand repayment following a covenant default. X4 says it needs additional capital; availability and terms are uncertain.
- Debt and liquidity conditions: X4 had borrowed $55.0 million under its Hercules facility, with a reported effective annual interest rate of 13.6%. The agreement requires at least $20.0 million of qualified cash through January 31, 2025; later requirements and a product-revenue performance covenant apply, subject to specified waivers. Additional borrowing capacity is conditional, including a tranche subject to lender discretion.
- Potential funding sources and obligations: The FDA granted a Priority Review Voucher (PRV) after approval; X4 intends to sell it, but timing and proceeds are uncertain and excluded from its cash projections. FDA approval also triggered a $7.0 million Genzyme milestone payment, due 30 days after approval. The Genzyme agreement includes up to $20.0 million in aggregate future milestones and tiered sales royalties.
- Development plans: X4 expected to present additional Phase 2 chronic-neutropenia data in June 2024 and planned to initiate a global Phase 3 trial in Q2 2024. It expected to submit an EMA application for WHIM syndrome in late 2024 or early 2025. These are forward-looking plans, not guarantees.
- Key business risks: Commercial uptake, reimbursement and the estimated WHIM patient population are uncertain. X4 depends on single third-party manufacturers for mavorixafor API and finished capsules, and on CROs and licensed intellectual property. Further capital raising may dilute shareholders or constrain operations. Clinical results, regulatory decisions and launch execution remain uncertain.
- Other disclosures: X4 reported no material legal proceedings, no defaults upon senior securities and effective disclosure controls as of March 31, 2024. No formal revenue or profitability guidance was provided.
Important facts for investors to verify
- Actual XOLREMDI launch sales, gross-to-net deductions, access and reimbursement, and whether uptake can support the debt covenants.
- Cash runway and covenant compliance, including whether X4 raises capital, draws eligible Hercules tranches or sells the PRV, and the resulting dilution or repayment implications.
- Timing and payment of the $7.0 million Genzyme milestone, as well as continuing royalties and other milestone exposure.
- Phase 2 results and execution of the planned Phase 3 and EMA submission; verify subsequent filings for updates.
- The Hercules tranche timing is described differently within the filing: the financial-statement note gives a first-drawing availability deadline of September 30, 2024, while MD&A states June 10, 2024. Confirm the operative loan terms and any amendments.